Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS
R Cofiell, A Kukreja, K Bedard, Y Yan… - Blood, The Journal …, 2015 - ashpublications.org
Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease
characterized by uncontrolled complement activation, systemic thrombotic microangiopathy …
characterized by uncontrolled complement activation, systemic thrombotic microangiopathy …
[HTML][HTML] Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial
F Fakhouri, M Hourmant, JM Campistol… - American journal of …, 2016 - Elsevier
Background Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening
disease of chronic uncontrolled complement activation leading to thrombotic …
disease of chronic uncontrolled complement activation leading to thrombotic …
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome
M Cugno, R Gualtierotti, I Possenti… - … of Thrombosis and …, 2014 - Wiley Online Library
Background Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy
characterized by hemolysis, platelet consumption, and renal injury. Eculizumab, a mAb that …
characterized by hemolysis, platelet consumption, and renal injury. Eculizumab, a mAb that …
[HTML][HTML] Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease
characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) …
characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) …
Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases
G Ardissino, S Testa, I Possenti, F Tel… - American Journal of …, 2014 - Elsevier
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic
microangiopathy, and as many as 70% of patients with aHUS have mutations in the genes …
microangiopathy, and as many as 70% of patients with aHUS have mutations in the genes …
[HTML][HTML] Atypical hemolytic uremic syndrome (aHUS): treating the patient
J Laurence - Clin Adv Hematol Oncol, 2013 - hematologyandoncology.net
The 3 major thrombotic microangiopathies (TMAs) are thrombotic thrombocytopenic purpura
(TTP), atypical hemolytic uremic syndrome (aHUS), and Shiga toxin–producing Escherichia …
(TTP), atypical hemolytic uremic syndrome (aHUS), and Shiga toxin–producing Escherichia …
Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab
J Schmidtko, S Peine, Y El-Housseini… - American Journal of …, 2013 - Elsevier
Uncontrolled complement activation is central to the occurrence of atypical hemolytic uremic
syndrome (aHUS) and can result in thrombotic microangiopathies (TMAs). These terms …
syndrome (aHUS) and can result in thrombotic microangiopathies (TMAs). These terms …
[HTML][HTML] Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
LA Greenbaum, M Fila, G Ardissino, SI Al-Akash… - Kidney international, 2016 - Elsevier
Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …
Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome
CM Legendre, C Licht, P Muus… - … England Journal of …, 2013 - Mass Medical Soc
Background Atypical hemolytic–uremic syndrome is a genetic, life-threatening, chronic
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …
disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion …
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome
GM Keating - Drugs, 2013 - Springer
The recombinant humanized monoclonal antibody eculizumab (Soliris®) is a complement
inhibitor that is indicated for use in the treatment of atypical haemolytic uraemic syndrome …
inhibitor that is indicated for use in the treatment of atypical haemolytic uraemic syndrome …